Postherpetic Neuralgia - Pipeline Review, H2 2016

  • ID: 3939697
  • Drug Pipelines
  • 98 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Aestus Therapeutics, Inc.
  • KPI Therapeutics, Inc.
  • Lpath, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • MORE
Postherpetic Neuralgia - Pipeline Review, H2 2016

Summary

‘Postherpetic Neuralgia - Pipeline Review, H2 2016’, provides an overview of the Postherpetic Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Postherpetic Neuralgia
- The report reviews pipeline therapeutics for Postherpetic Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Postherpetic Neuralgia therapeutics and enlists all their major and minor projects
- The report assesses Postherpetic Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Postherpetic Neuralgia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Postherpetic Neuralgia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Postherpetic Neuralgia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Aestus Therapeutics, Inc.
  • KPI Therapeutics, Inc.
  • Lpath, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Postherpetic Neuralgia Overview

Therapeutics Development

Pipeline Products for Postherpetic Neuralgia - Overview

Postherpetic Neuralgia - Therapeutics under Development by Companies

Postherpetic Neuralgia - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Postherpetic Neuralgia - Products under Development by Companies

Postherpetic Neuralgia - Companies Involved in Therapeutics Development

Aestus Therapeutics, Inc.

ContraVir Pharmaceuticals, Inc.

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

Immune Pharmaceuticals Inc.

Jiangsu Hengrui Medicine Co., Ltd.

KPI Therapeutics, Inc.

Lpath, Inc.

Merck & Co., Inc.

Patagonia Pharmaceuticals, LLC

Pfizer Inc.

Phosphagenics Limited

Relmada Therapeutics, Inc.

Scilex Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Toray Industries, Inc.

Postherpetic Neuralgia - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(clonidine hydrochloride + naltrexone hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATX-08001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-746 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-05195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

funapide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FV-100 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride patch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lpathomab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mepivacaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mirogabalin besylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-8291 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATN-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pregabalin SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REL-1017 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRK-700 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

U-2902 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Postherpetic Neuralgia - Dormant Projects

Postherpetic Neuralgia - Discontinued Products

Postherpetic Neuralgia - Product Development Milestones

Featured News & Press Releases

Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles

May 12, 2016: SCILEX Pharmaceuticals Study Suggests Underutilization of Recommended First-Line Lidocaine Patches and Opioid Overuse for Treatment of Pain Associated with Post-Herpetic Neuralgias

Apr 22, 2016: SCILEX Pharmaceuticals Reports First-Line Treatments Including Lidocaine Patches for Post-Herpetic Neuralgia Are Significantly Underutilized

Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study

Dec 10, 2015: SCILEX Pharmaceuticals Announces Executive Hires

Sep 16, 2015: FDA Accepts SCILEX Pharmaceuticals' NDA Filing for ZTlido

Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial

Apr 02, 2015: Teva and Xenon Announce Enrollment of First Patient in a Phase 2b Study Evaluating TV-45070 for Postherpetic Neuralgia

Feb 20, 2015: ContraVir Pharmaceuticals Provides Clinical Update on FV-100

Feb 19, 2015: Xenon Pharmaceuticals Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia

Feb 04, 2015: Daiichi Sankyo Announces First Patients in Large-scale, Multi-national Phase 3 Clinical Programs for Mirogabalin

Jan 07, 2015: ContraVir Pharmaceuticals Granted FDA Meeting to Discuss Proposal for Phase 3 Trial of FV-100

Dec 18, 2014: Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia

Aug 11, 2014: Scilex Pharmaceuticals Completes Trial Enrollment for Ztlido

Jul 14, 2014: SCILEX Pharmaceuticals Commences Dermal Safety Studies of Ztlido

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Postherpetic Neuralgia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Postherpetic Neuralgia - Pipeline by Aestus Therapeutics, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by ContraVir Pharmaceuticals, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016

Postherpetic Neuralgia - Pipeline by Daiichi Sankyo Company, Limited, H2 2016

Postherpetic Neuralgia - Pipeline by Immune Pharmaceuticals Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016

Postherpetic Neuralgia - Pipeline by KPI Therapeutics, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Lpath, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Merck & Co., Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Patagonia Pharmaceuticals, LLC, H2 2016

Postherpetic Neuralgia - Pipeline by Pfizer Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Phosphagenics Limited, H2 2016

Postherpetic Neuralgia - Pipeline by Relmada Therapeutics, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016

Postherpetic Neuralgia - Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016

Postherpetic Neuralgia - Pipeline by Toray Industries, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Postherpetic Neuralgia - Dormant Projects, H2 2016

Postherpetic Neuralgia - Dormant Projects (Contd..1), H2 2016

Postherpetic Neuralgia - Dormant Projects (Contd..2), H2 2016

Postherpetic Neuralgia - Discontinued Products, H2 2016 87List of Figures

Number of Products under Development for Postherpetic Neuralgia, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Aestus Therapeutics, Inc.
  • KPI Therapeutics, Inc.
  • Lpath, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Phosphagenics Limited
  • MORE
Postherpetic Neuralgia Postherpetic neuralgia is a complication of shingles, which is caused by the chickenpox (herpes zoster) virus. Signs and symptoms may include pain, sensitivity to light touch, itching and numbness and weakness or paralysis. The predisposing factors include age, people with HIV and Hodgkin’s lymphoma. Treatment includes anticonvulsants, antidepressants and opioid painkillers.

Postherpetic Neuralgia pipeline therapeutics constitutes close to 23 molecules. which approximately 23 molecules are developed by Companies. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 7, 3, 7 and 1 respectively.

Our latest report Postherpetic Neuralgia – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Postherpetic Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Postherpetic Neuralgia and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Aestus Therapeutics, Inc.
ContraVir Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
Immune Pharmaceuticals Inc.
Jiangsu Hengrui Medicine Co., Ltd.
KPI Therapeutics, Inc.
Lpath, Inc.
Merck & Co., Inc.
Patagonia Pharmaceuticals, LLC
Pfizer Inc.
Phosphagenics Limited
Relmada Therapeutics, Inc.
Scilex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Ltd.
Toray Industries, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll